#USA #Shine #Lantheus #Janesville #SPECT

SHINE's Strategic Expansion in Nuclear Medicine

Introduction
In a transformative move within the nuclear medicine sector, SHINE Technologies has successfully acquired the SPECT business from Lantheus. This acquisition, announced on January 2, 2026, positions SHINE to strengthen its market presence and operational capabilities significantly. Furthermore, to spearhead this new venture, Michael Rossi has been appointed as the CEO of SHINE SPECT USA, LLC.

Details of the Acquisition
The acquisition includes Lantheus' manufacturing facility located in North Billerica, Massachusetts, alongside its extensive portfolio of diagnostic radiopharmaceuticals. Notably, the facility has manufactured the TechneLite® (Technetium Tc 99m Generator) for an impressive 55 years. This product, along with imaging agents like Cardiolite® and NEUROLITE®, serves hospitals and imaging centers throughout North America, contributing to millions of diagnostic procedures in various medical fields, including cardiology and pulmonology.

Greg Piefer, the founder and CEO of SHINE Technologies, highlighted the necessity for modernization within the nuclear medicine supply chain to align better with evolving patient needs. He stated, “We’re building that now, bringing new technology to bear across both diagnostic and therapeutic markets.”

Meet the New Leader
Michael Rossi comes to SHINE with substantial experience in the radiopharmaceutical domain. He previously served as President and CEO of Y-mAbs Therapeutics, leading the company through significant growth and a successful acquisition by SERB Pharmaceuticals. Before that, he held key positions with companies such as Advanced Accelerator Applications and GE Healthcare’s Global SPECT Segment, demonstrating a robust track record in the industry.

“My excitement to join SHINE at this pivotal moment is immense,” remarked Rossi. He recognizes the strengths of the existing SPECT team, which has cultivated excellent customer relations and operational excellence over decades. Rossi emphasizes that combining these assets with SHINE’s production capabilities will create a robust platform to meet the nuclear medicine market's needs effectively.

The Future of Nuclear Medicine with SHINE
The strategic move comes at a critical juncture as SHINE also develops its Chrysalis facility in Janesville, Wisconsin, which aims to become the largest isotope production facility globally. This facility will utilize fusion-based technology to produce molybdenum-99 (Mo-99), crucial for producing Technetium-99m, the most widely used medical isotope in the world. The integration of the SPECT business with the Chrysalis facility is expected to create a seamless supply chain from production to distribution, effectively enhancing the security and availability of diagnostic imaging isotopes.

SHINE's nuclear medicine platform is thus poised to address both diagnostic and therapeutic needs comprehensively. With its current capabilities, including one of the largest Lu-177 production facilities in the western hemisphere, SHINE stands ready to deliver an integrated supply of isotopes essential for treating conditions like cancer.

Conclusion
SHINE’s acquisition of Lantheus' SPECT business represents a significant leap forward for the company, enhancing its portfolio and solidifying its role as a leader in nuclear medicine. With Michael Rossi at the helm of SHINE SPECT USA, the company is set to navigate the evolving landscape of the nuclear medicine market, bringing innovative solutions to patients and healthcare providers alike. As SHINE continues to pioneer advancements in nuclear medicine, patients can look forward to improved diagnostic capabilities and enhanced treatment options.

For more on SHINE Technologies and their initiatives in the nuclear medicine sector, visit SHINE's Website.